Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin

摘要: Background Statin therapy might modestly increase the risk of new-onset T2DM. Methods We used a standard definition diabetes and excluded patients with prevalent at baseline. identified baseline predictors T2DM compared event rates in without newonset Results In TNT (Treating to New Targets) trial, 351 3,798 randomized 80 mg atorvastatin 308 3,797 10 developed (9.24% vs. 8.11%, adjusted hazard ratio [HR]: 1.10, 95% confidence interval [CI]: 0.94 1.29, p 0.226). IDEAL (Incremental Decrease End Points Through Aggressive Lipid Lowering) 239 3,737 mg/day 208 3,724 simvastatin 20 (6.40% 5.59%, HR: 1.19, CI: 0.98 1.43, 0.072). SPARCL (Stroke Prevention by Reduction Cholesterol Levels) 166 1,905 115 1,898 placebo group (8.71% 6.06%, 1.37, 1.08 1.75, 0.011). each 3 trials, fasting blood glucose, body mass index, hypertension, triglycerides were independent Across major cardiovascular events occurred 11.3% 10.8% (adjusted 1.02, 0.77 1.35, 0.69). Conclusions High-dose treatment trial is associated slightly increased Baseline glucose level features metabolic syndrome are predictive across trials. (J Am Coll Cardiol 2011;57:1535‐45) © 2011 American College Cardiology Foundation